On the topic of translational and clinical relevance, we remark that beyond BRAFV600E-mutant melanoma, the BRAFV600E–MEK–ERK pathway is also a target for treating non-small-cell lung carcinoma, thyroid cancer, and paediatric high-grade glioma with the BRAFV600E mutation63,64. Here, MAP2K7 is linked to thyroid gland carcinoma.